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A growing number of studies have reported health benefits from oral supplementation with bovine 53 milk fat globule membranes (MFGM) to humans of different age groups, including infants (1) . 54 MFGM is the membrane surrounding the secreted fat droplets in milk. It is released by a unique 55 mechanism in the mammary gland and is composed by a triple phospholipid and cholesterol layer with 56 incorporated proteins and glycoproteins (2) . A schematic drawing of fat release and MFGM 57 composition is showed in Figure 1 . The genes regulating MFGM synthesis are conserved across 58 species indicating a functional benefit of the fraction in milk (3), even if the exact MFGM composition 59 varies between species. Phospholipids make up 30% of the total milk lipid weight with 60 sphingomyelins, phosphatidylcholines and phosphatidylethanolamines contributing approximately one 61 third each (2) . Almost all milk gangliosides are also located in the MFGM (4) . The proteome of the 62 human MFGM includes 191 different identified proteins including mucins, butyrophilin, lactoferrin 63 and lactadherin (5) . In a study on bovine MFGM-rich fractions, 244 proteins were identified in a whey 64 protein concentrate and 133 in a buttermilk protein concentrate (6) . MFGM is also rich in sialic acid as 65 part of gangliosides (4) and glycosylated proteins. 66
Breast-fed infants have a higher intake of MFGM components compared to their formula-fed 67 counterparts because traditionally, the MFGM fraction is discarded with the milk fat when this is 68 replaced by vegetable oils as the fat source in infant formulas. Following advances in dairy 69 technology, bovine MFGM concentrates are now commercially available and possible to use as a 70 supplement to foods including infant formulas. MFGM has emerged as a complex factor that may 71 explain some of the differences observed between breast-fed and formula-fed infants. 72
Possible biological effects of MFGM components 75
The rationale for MFGM supplementation of infant formula is based on a growing number of studies 76
showing health benefits of individual components of the MFGM, mostly in animal models, and a 77 limited number of human studies on supplementation with different MFGM fractions. 78
Dietary gangliosides (7), sialic acid (8) and sphingomyelin (9) have been shown to be important for 79 optimal brain development and function in different animal models. However, it should be noted that 80 some of these models are disease models or models with inhibited de novo synthesis, which is far from 81 supplementing a healthy infant. In a small study on premature infants with a birth weight < 1500 g, 82 infants receiving formula with high sphingomyelin content (20 % vs. 13 % of all phospholipids in 83 milk) to cover shortages of breast milk performed better at neurobehavioural follow-up between 6-18 84 months corrected age (10) . Further, oral sphingomyelin increased maturation of the intestine in rats 85 (11) . Gangliosides have also been suggested to play an important role in the development of intestinal 86 microbiota composition, gut immunity and, consequently, in the defense against infections (12) . Other 87 components of MFGM are also involved in the defense against infections, e.g. the glycoproteins 88 butyrophilin, lactadherin and mucins (13, 14) all have anti-microbial effects, the lipid fraction of 89 bovine MFGM has antiviral effect in vitro (15) , and oligosaccharides inhibit binding of several 90 bacteria (including pneumococci) to the mucosa. (14) . Both lipid and protein components of MFGM 91 have anticancer effects in vitro (13) . 92
93
Dietary MFGM to adults and children after weaning 94
In human adults, most studies on dietary MFGM have focused on outcomes related to different risk 95 factors for cardiovascular disease. Buttermilk consumption reduced serum cholesterol concentrations, 96 primarily through inhibition of intestinal absorption of cholesterol (16) and decreased blood pressure 97 and angiotensin-I-converting enzyme in moderately hypercholesterolemic adults (17) . In contrast to 98 milk fat without MFGM, milk fat enclosed by MFGM did not impair the lipoprotein profile inoverweight adults (18) . Addition of an MFGM fraction to a high-saturated fat meal reduced the 100 postprandial insulinemic and inflammatory response in overweight and obese adults (19) . Dietary 101 MFGM given to healthy adults have also been shown to have positive effects on gastrointestinal 102 symptoms from diarrheagenic E coli (20) and on muscle strength (21) . 103
A few randomized studies on dietary MFGM supplementation of children after weaning have been 104
published. In a Peruvian study, an MFGM-enriched protein fraction given to healthy, primarily breast-105 fed 6-11-mo-old infants during 6 months, decreased the longitudinal prevalence of diarrhea (3.84% vs. 106 4.37%, p<0.05) and the incidence of bloody diarrhea (OR =0.59, 95%CI 0.34-1.02, p=0.025) (22) . In 107 contrast, a daily dose of milk powder supplemented with 2 g of a spray-dried ganglioside concentrate 108
given to infants 8-24 months of age for 12 weeks in India, did not affect diarrheal morbidity (23) . In a 109
Belgian study, a phospholipid-rich MFGM concentrate given daily for 4 months to pre-school children 110 aged 2.5 to 6 years decreased behavioral problems and reduced days with fever during the intervention 111 period (24) . 112
113
Supplementation with MFGM to term infants in early infancy 114
Three randomized controlled trials on MFGM supplementation to infant formula given to term infants 115 during the first half-year of life were identified in a search on PubMed performed 1 st of September 116 2016 (Table 1) . 117
In a double-blinded randomized controlled trial (DBRCT) in Indonesia, Gurnida et al evaluated the 118 impact on cognitive function of feeding a standard infant formula enriched with bovine milk 119 gangliosides, provided as a complex bovine milk lipid fraction (AnmumInfacare, Fonterra Cooperative 120 Group, Auckland, New Zealand) increasing the ganglioside content from 6 to 9 mg/L, compared to the 121 same formula without enrichment (control group), from 2 to 8 weeks (baseline) until 24 weeks of age 122 (25) . A total of 70 healthy, term infants were randomized to either ganglioside supplemented (n=35; 123 29 completed the study) formula or control (n=35; 30 completed the study) formula. A breast-fed 124 reference group (n=40; 32 completed the study) was also recruited. Primary outcome was the Griffiths In a DBRCT in Umeå, Sweden, formula-fed healthy term infants were randomized to receive an 132 experimental formula (n=80; 73 completed the study) supplemented with a protein-rich MFGM 133 fraction (Lacprodan® MFGM-10, Arla Foods Ingredients, Viby, Denmark) or a control formula 134 (n=80; 68 completed the study) from <2 to 6 months of age. The experimental formula had lower 135 energy density (60 vs. 66 kcal/100 mL) and protein concentration (1.20 vs. 1.27 g/100 mL), and 136
MFGM-proteins made up 4% (wt/wt) of the total protein content of the formula. A breast-fed 137
reference group was also recruited (n=80; 72 fulfilled the study). Primary outcomes were weight at 6 138 months of age and psychological assessment using Bayley Scales of Infant Development, 3
rd Ed 139 (Bayley-III). The formula-fed infants regulated their ingested volumes by increasing meal size, 140 resulting in no differences in energy intake, protein intake, blood urea nitrogen, s-insulin or growth, 141 including body fat percent, up to 12 months of age (26, 27) . At 12 months of age, the MFGM-142 supplemented group received higher scores (mean ± SD) in the cognitive domain of Bayley-III (105.8 143 ± 9.2) than the control group (101.8 ± 8.0, p=0.008) and did not differ from the breast-fed reference 144 group (106.4 ± 9.5, p=0.73) (26) . There were no observed differences in socioeconomic background 145 factors between the MFGM-supplemented and control formula groups. During the intervention, the 146 MFGM-supplemented group had a lower incidence of acute otitis media than the control group (1% 147 vs. 9%, p=0.034), lower incidence and longitudinal prevalence of antipyretic use and lower 148 concentrations of s-IgG against pneumococci after vaccination (28). During the intervention, the 149 MFGM-supplemented group gradually reached higher serum cholesterol concentrations than the 150 control group and did not differ from the breast-fed reference group at 6 months of age (29) . 151
In a multicenter non-inferiority DBRCT on 199 (149 completed the intervention) healthy term infants, 152 protein-rich (MFGM-P) bovine MFGM fraction, respectively (30) . At 14 days of age, the infants were 154 randomized to receive standard infant formula (control), standard formula enriched with MFGM-L 155 (Fonterra Co-operative Group Limited, Auckland, New Zealand), or standard formula enriched with 156 MFGM-P (Lacprodan® MFGM-10, Arla Foods Ingredients, Viby, Denmark) until 4 mo of age. 157
Primary outcome, weight gain, was non-inferior in the MFGM-L and MFGM-P groups compared with 158 the control group. Among secondary and exploratory outcomes, few between-group differences were 159 observed. Adverse events and morbidity rates were similar across groups except for a higher rate of 160 eczema in the MFGM-P group (13.9% vs. 1.4% in the MFGM-L group and 3.5% in the control group, 161 p=0001). However, the limited number of observations and the lack of a systematic eczema scoring 162 system make this result uncertain. In the Swedish study, no increased risk of rash was observed (31) . be considered quite limited. One of the studies had a small number of study subjects (25) , and the 171 study population in the other study (26) Non-inferior weight gain for both groups up to 4 months.
Higher rate of eczema in the MFGM-P group.
